DHX9 and plasma cell myeloma: Knockdown of DHX9 in a representative panel of human cancer cell lines, including multiple myeloma, osteosarcoma, and breast, lung, and cervical cancer cells, demonstrated that DHX9 suppression was detrimental in the majority of cancer cells [18].